Factor VIII Inhibitor - Pipeline Insight, 2018

  • ID: 4382524
  • Drug Pipelines
  • Region: Global
  • 49 pages
  • DelveInsight
until Dec 31st 2018
1 of 4


  • Ablynx
  • Ajinomoto
  • Archemix Corporation
  • BioVascular
  • Glenmark
  • Sanofi
  • MORE

Factor VIII Inhibitor - Pipeline Insights, 2018 report outlays comprehensive insights of present scenario and growth prospects across Factor VIII Inhibitor. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of two active products i.e. Caplacizumab of Ablynx and SHP655 of Shire.

Products covered by Phase

  • Filed & Phase III
  • Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Factor VIII Inhibitor

  • Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
  • Therapeutic segmentation of products for Factor VIII Inhibitor
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.


Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report

  • Provides an overview of therapeutic pipeline activity for Factor VIII Inhibitor across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Factor VIII Inhibitor therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Factor VIII Inhibitor

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across Factor VIII Inhibitor to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Factor VIII Inhibitor R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Factor VIII Inhibitor to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs
Note: Product cover images may vary from those shown
2 of 4


  • Ablynx
  • Ajinomoto
  • Archemix Corporation
  • BioVascular
  • Glenmark
  • Sanofi
  • MORE
  • Overview
  • Factor VIII
  • Structure
  • A-Domain
  • B-Domain
  • C-Domain
  • Mechanism of Action
  • Factor VIII Mutation
  • Indications related to Factor VIII
  • Thrombotic thrombocytopenic purpura (TTP)
  • Thrombosis
  • Acute coronary syndrome
  • Factor VIII/ von Willebrand Factor Complex
  • Pipeline Therapeutics
  • Late Stage Products (Filed & Phase III)
  • Comparative Analysis
  • Caplacizumab: Ablynx
  • Product Description
  • Research and Development
  • Product Development Activities
  • The list continues…
  • Inactive Products
  • Comparative Analysis
  • Appendix
List of Tables
Table 1: Late Stage Products (Filed & Phase III)
Table 2: Inactive Products

List of Figures
Figure 1: Late Stage Products (Filed & Phase III)
Figure 2: Inactive Products
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Ablynx
  • Shire
  • ThromboGenics
  • Ajinomoto
  • BioVascular
  • Archemix Corporation
  • Glenmark
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown